ClinicalTrials.gg
RecruitingNCT05084196Updated Dec 17, 2025

Melatonin for Prevention of Kidney Injury

A Phase 3 interventional study of Melatonin and Placebo Capsule in Acute Kidney Injury and Adverse Drug Event, sponsored by Rutgers, The State University of New Jersey. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Rutgers, The State University of New Jersey · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
52nd of 237
300 · median 67
Started
2023
with 13 others
Phase 3
20 of 370
3 open now
Primary completion
2027-06
later than 42 of 87 live
Registered
263rd of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 52nd largest by planned enrollment of the 237 interventional ones that give a count, is one of 14 that started in 2023, is one of 20 in phase 3, reaches primary completion later than 42 of the 87 other live ones, and was the 263rd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and effectiveness of melatonin for the prevention of antibiotic associated acute kidney injury in hospitalized patients.

Read the detailed description

Consenting subjects meeting inclusion and exclusion will be randomized to receive melatonin 5 mg daily or a matching placebo. Study subjects will be followed for the duration of hospitalization or discontinuation of broad spectrum antibiotics (vancomycin plus piperacillin/tazobactam). The primary outcome and secondary outcomes will be evaluated by the study team.

03

Conditions studied

  • Acute Kidney Injury
  • Adverse Drug Event
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 75 years
  • Currently prescribed vancomycin with the presumption that therapy will be continued for at least 3 days based on a review of subject status. Because of the critical nature of starting empiric broad-spectrum antibiotics, we will allow one dose of the antibiotic combination before consent and enrollment. This strategy is necessary for the ethical conduct of the study.

Exclusion criteria

Exclusion criteria:

  • Estimated \< 30 mL/min
  • Liver impairment (liver enzymes > 3 times upper limit)
  • Any history of allergy or to melatonin
  • Pregnancy or breastfeeding
  • disease
  • Requiring vasopressors
  • Requiring mechanical ventilation
  • History of acute kidney injury in the past 30 days
  • Inability to take oral medications
  • Clinical evidence of significant unstable or uncontrolled illness which, in the opinion of the research team, could confound the results of the study or put the patient at undue risk.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Melatonin Arm

    Melatonin 5 mg capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.

    Drug: Melatonin

  • Placebo comparator
    Placebo Arm

    Placebo capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.

    Other: Placebo Capsule

Interventions

  • Melatonin 5 mg capsule by mouth at bedtime

  • OtherPlacebo Capsule

    Placebo capsule by mouth at bedtime

06

What researchers measure

Primary outcomes

  1. Acute kidney injury

    Acute kidney injury will be defined as an increase in sCr from baseline of \>/= 0.3 mg/dL or a \>/= 50% increase from baseline.

    Time frame: From date of randomization until the date of first documented acute kidney injury or date of antibiotic discontinuation, whichever came first, assessed up to 28 days

Other outcomes

  1. Melatonin plasma trough concentration

    Evaluate the steady state plasma trough concentration of melatonin

    Time frame: Days 3, 5, and 7

  2. Piperacillin/tazobactam plasma trough concentration

    Evaluate the steady state plasma trough concentration of piperacillin/tazobactam

    Time frame: Days 3, 5, and 7

  3. Vancomycin plasma Area Under the Curve (AUC)

    Evaluate the steady state plasma AUC of vancomycin

    Time frame: Days 3, 5, and 7

  4. Association between Kidney Injury Molecule-1 (KIM-1) and serum creatinine

    Measure KIM-1 in plasma and urine and evaluate discordance between serum creatinine.

    Time frame: Days 3, 5, and 7

  5. Mitochondrial stress assessment via extracellular flux analysis to measure oxygen consumption rate of cells

    Evaluate mitochondrial stress in peripheral blood mononuclear cells from a subset of subjects in each group. In addition, mitochondrial stress will be evaluated on day 3 in a subset in the melatonin group.

    Time frame: Days 1 and 3

  6. Urine mitochondrial DNA copy number

    Measure mitochondrial DNA (mtDNA) in urine samples using polymerase chain reaction (PCR).

    Time frame: Days 1, 3, 5, and 7

  7. Fold-change in NRF-2 gene expression in peripheral blood mononuclear cells

    Measure gene expression level at baseline and then on day 5 (or last day of study if earlier) using polymerase chain reaction (PCR) and compare the fold-change from baseline between groups.

    Time frame: Days 1 and 5

  8. Number of subjects with NRF2 DNA single nucleotide polymorphisms

    Determination of the number of individuals with NRF2 DNA single nucleotide polymorphisms in the study population and compare the incidence of primary outcome in those with and without polymorphisms.

    Time frame: Day 1

  9. Number of subjects with KEAP1 DNA single nucleotide polymorphisms

    Determination of the number of individuals with KEAP1 DNA single nucleotide polymorphisms in the study population and compare the incidence of primary outcome in those with and without polymorphisms.

    Time frame: Day 1

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 47 months after the start.

Of 35 phase 3 interventional studies under Acute Kidney Injury, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Oct 19, 2021
StartActual
Jun 5, 2023
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05084196
Responsible party
Luigi Brunetti (Associate Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Oct 19, 2021
Start date
Jun 5, 2023
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 17, 2025

Study contacts

Luigi Brunetti, PhD
Contact
luigi.brunetti@rutgers.edu
908-595-2645
Luigi Brunetti, PhD
principal investigator · Rutgers, The State University of New Jersey

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion